Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-versus-host Disease

Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome

Bone Marrow Transplantation volume 50, pages 127–133 (2015)Cite this article

Subjects

Abstract

The aim of this study was to investigate the impact of occurrence of chronic GVHD (cGVHD) and its severity on transplantation outcomes in a consecutive cohort of AML and myelodysplastic syndrome (MDS) patients who received unmanipulated haploidentical hematopoietic SCT (haplo-HSCT; n=324). The cumulative incidence of relapse was significantly decreased in patients with cGVHD compared with the non-cGVHD group (1 year: 3.2% vs 11.9%, P=0.002; 3 years: 6.0% vs 16.3%, P=0.002), particularly in those with mild cGVHD. The cumulative incidence of non-relapse mortality was comparable between patients with and without cGVHD. The probabilities of disease-free survival (DFS) were significantly better in patients with cGVHD than in those in the non-cGVHD group (1 year: 90.5% vs 78.5%, P=0.002; 3 years: 86.5% vs 71.5%, P<0.001), particularly in those with mild or moderate cGVHD; however, no significant impact of severe cGVHD on DFS was seen. Our findings highlight the close relationship between cGVHD and the immune-mediated GVL effect in patients with AML and MDS receiving unmanipulated haplo-HSCT; however, only mild or moderate cGVHD was associated with a lower risk of relapse translating into improved DFS.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. van Besien K . Allogeneic transplantation for AML and MDS: GVL versus GVHD and disease recurrence. Hematology Am Soc Hematol Educ Program 2013; 2013: 56–62.

    Article  PubMed  Google Scholar 

  2. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720–1728

    CAS  PubMed  Google Scholar 

  3. Weisdorf D, Zhang MJ, Arora M, Horowitz MM, Rizzo JD, Eapen M . Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. Biol Blood Marrow Transplant 2012; 18: 1727–1733

    Article  PubMed  PubMed Central  Google Scholar 

  4. Baron F, Labopin M, Niederwieser D, Vigouroux S, Cornelissen JJ, Malm C et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia 2012; 26: 2462–2468

    Article  CAS  PubMed  Google Scholar 

  5. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217

    Article  CAS  PubMed  Google Scholar 

  6. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956

    Article  PubMed  Google Scholar 

  7. Cho BS, Min CK, Eom KS, Kim YJ, Kim HJ, Lee S et al. Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia 2009; 23: 78–84

    Article  PubMed  Google Scholar 

  8. Kim DY, Lee JH, Lee JH, Kim SH, Lim SN, Kim SD et al. Reevaluation of the National Institutes of Health criteria for classification and scoring of chronic GVHD. Bone Marrow Transplant 2010; 45: 1174–1180

    Article  PubMed  Google Scholar 

  9. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641–650

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Di Bartolomeo P, Santarone S, De Angelis G, Picardi A, Cudillo L, Cerretti R et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood 2013; 121: 849–857

    Article  CAS  PubMed  Google Scholar 

  11. Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006; 107: 3065–3073

    Article  CAS  PubMed  Google Scholar 

  12. Xiao-Jun H, Lan-Ping X, Kai-Yan L, Dai-Hong L, Yu W, Huan C et al. Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies. Clin Cancer Res 2009; 15: 4777–4783

    Article  PubMed  Google Scholar 

  13. Wang Y, Liu DH, Liu KY, Xu LP, Zhang XH, Han W et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer 2013; 119: 978–985.

    Article  PubMed  Google Scholar 

  14. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006; 38: 291–297

    Article  PubMed  Google Scholar 

  15. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W et al. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009; 15: 257–265

    Article  CAS  PubMed  Google Scholar 

  16. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloidleukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075–4083

    CAS  PubMed  Google Scholar 

  17. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088

    CAS  PubMed  Google Scholar 

  18. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Gooley TA, Leisenring W, Crowley J, Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695–706

    Article  CAS  PubMed  Google Scholar 

  20. Scrucca L, Santucci A, Aversa F . Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 2010; 45: 1388–1395

    Article  CAS  PubMed  Google Scholar 

  21. Terwey TH, Le Duc TM, Hemmati PG, le Coutre P, Nagy M, Martus P et al. NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia. Ann Oncol 2013; 24: 1363–1370

    Article  CAS  PubMed  Google Scholar 

  22. Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002; 100: 406–414

    Article  CAS  PubMed  Google Scholar 

  23. Signori A, Crocchiolo R, Oneto R, Sacchi N, Sormani MP, Fagioli F et al. Chronic GVHD is associated with lower relapse risk irrespective of stem cell source among patients receivingtransplantation from unrelated donors. Bone Marrow Transplant 2012; 47: 1474–1478

    Article  CAS  PubMed  Google Scholar 

  24. Saillard C, Crocchiolo R, Furst S, El-Cheikh J, Castagna L, Signori A et al. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen. Leuk Lymphoma 2014; 55: 1106–1112

    Article  CAS  PubMed  Google Scholar 

  25. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447–3454

    Article  PubMed  Google Scholar 

  26. Federmann B, Bornhauser M, Meisner C, Kordelas L, Beelen DW, Stuhler G et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study. Haematologica 2012; 97: 1523–1531

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Mo XD, Xu LP, Liu DH, Chen YH, Zhang XH, Chen H et al. Health related quality of life among patients with chronic graft-versus-host disease in China. Chin Med J (Engl) 2013; 126: 3048–3052

    Google Scholar 

  28. Arai S, Jagasia M, Storer B, Chai X, Pidala J, Cutler C et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood 2011; 118: 4242–4249

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Mo XD, Xu LP, Liu DH, Zhang XH, Chen H, Chen YH et al. The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) is an outcome predictor for partially matched related donor transplantation. Am J Hematol 2013; 88: 497–502.

    Article  PubMed  Google Scholar 

  30. Huang XJ, Liu DH, Liu KY, Xu LP, Chen YH, Wang Y et al. Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia. J Clin Immunol 2008; 28: 276–283

    Article  CAS  PubMed  Google Scholar 

  31. Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 2013; 19: 117–122

    Article  CAS  PubMed  Google Scholar 

  32. Martelli MF, Di Ianni M, Ruggeri L, Pierini A, Falzetti F, Carotti A et al. ‘Designed’ grafts for HLA-haploidentical stem cell transplantation. Blood 2014; 123: 967–973

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Editage for their assistance in editing this manuscript.This work was supported by the Beijing Municipal Science and Technology Program (grant Z111107067311070), the Clinical Characteristic Study of Capital Project (grant Z121107001012085) and the Key Program of the National Natural Science Foundation of China (grant 81230013).

Author information

Authors and Affiliations

  1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China

    X-D Mo, L-P Xu, X-H Zhang, D-H Liu, Y Wang, H Chen, C-H Yan, Y-H Chen, W Han, F-R Wang, J-Z Wang, K-Y Liu & X-J Huang

  2. Peking-Tsinghua Center for Life Sciences, Beijing, China

    X-J Huang

Authors
  1. X-D Mo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L-P Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. X-H Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D-H Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C-H Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y-H Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. W Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. F-R Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J-Z Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. K-Y Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. X-J Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to X-J Huang.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mo, XD., Xu, LP., Zhang, XH. et al. Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome. Bone Marrow Transplant 50, 127–133 (2015). https://doi.org/10.1038/bmt.2014.223

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2014.223

This article is cited by

Search

Advanced search

Quick links